Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Similar documents
Indolent Lymphomas: Current. Dr. Laurie Sehn

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Hodgkin's Lymphoma. Symptoms. Types

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

Lymphoma: The Basics. Dr. Douglas Stewart

Lymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Non-Hodgkin lymphoma

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

Lymphomas and multiple myeloma 12/23/2018 1

Change Summary - Form 2018 (R3) 1 of 12

Lymphatic system component

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Corporate Medical Policy

Indium-111 Zevalin Imaging

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

Hodgkin Lymphoma PROVIDING THE LATEST INFORMATION FOR PATIENTS & CAREGIVERS. Revised 2018

Head and Neck: DLBCL

T-cell Lymphomas Biology and Management

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center

B Cell Lymphoma: Aggressive

Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma (Lymphosarcoma) by Pamela A. Davol

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Lymphoma John P. Leonard, M.D.

HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)

Non-Hodgkin Lymphoma in Clinically Difficult Situations

Treating Hodgkin Lymphoma

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma

Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???

Relapsed/Refractory Hodgkin Lymphoma

CLINICAL MEDICAL POLICY

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li,

Diagnosis and patient pathway in lymphomas

Relapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma

SURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY

Monsanto s Spin on its Roundup herbicide is Unwinding

The Lymphoma Guide Information for Patients and Caregivers

Update in Lymphoma Imaging

NCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12

HODGKIN DISEASE. What is cancer?

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey

Non-Hodgkin s Lymphoma

NON- HODGKIN LYMPHOMA

2012 by American Society of Hematology


1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page

Lymphomas: Current Therapy Approaches

Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)

Alexander Fosså, M.D. PhD.

East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma)

CLL: A Guide for Patients and Caregivers CHRONIC LYMPHOCYTIC LEUKEMIA

LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital

Hodgkin Lymphoma. Erica, Hodgkin lymphoma survivor

Pediatric Oncology. Vlad Radulescu, MD

Lymphoma Read with the experts

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas

Aggressive B-Cell Lymphomas

Lymphoma: What You Need to Know

Aggressive B-cell Lymphoma 2013

Update: Non-Hodgkin s Lymphoma

Immunopathology of Lymphoma

Chronic Lymphocytic Leukemia (CLL)

Lugano classification: Role of PET-CT in lymphoma follow-up

Professor Mark Bower

Recent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany

Patient Case Studies & Panel Discussion

Acute: Symptoms that start and worsen quickly but do not last over a long period of time.

Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy?

Lymphoma- Med A-new drugs and treatments

12/22/2017 Patient education: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics) - UpToDate

WHAT ARE PAEDIATRIC CANCERS

Surviving Leukemia And Hodgkin's Lymphoma: An Overview Of Effective Treatment Methods By Melinda Baxter

Opdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for?

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas

CLINICAL MEDICATION POLICY

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

CLINICAL MEDICATION POLICY

Medical Policy Manual. Date of Origin: May Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas

ARRO Case: Pediatric High Risk Classical Hodgkin Lymphoma

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

Case Report B Cell Lymphoma, Unclassifiable, Transformed from Follicular Lymphoma: A Rare Presentation with Review of the Literature

HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Diffuse large B-cell lymphomas. G. Verhoef, MD, PhD University Hospital Leuven BHS, March 9, 2013

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Transcription:

Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Conflicts of interest I have no conflicts of interest to declare

Outline What does aggressive lymphoma mean? How do we diagnose it? How to we predict how it will behave? How do we treat it? What can you expect with treatment?

Categories of lymphoma Indolent Aggressive Other/Special/Unique

Why does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks Treatment generally given with the expectation of remission, goal of possible cure

Aggressive lymphomas Incidence (per 100,000) Diffuse large B cell 6.9 Hodgkin 2.7 T cell lymphomas 2.1 Mantle cell lymphoma 0.8 Burkitt lymphoma 0.4 Gray zone lymphoma <0.1 SEER Database Incidence 2011-12

Lymphocytes B cells develop in the bone marrow form antibodies against foreign bodies 90% of all lymphomas T cells mature in the thymus gland orchestrate the immune response 10% of lymphomas NK (natural killer) cells destroy viruses and cancers through direct attack Very rare lymphomas

Not only in lymph nodes Nodal Neck Supraclavicular Axillary Groin Spleen Extranodal GI tract (stomach) Bone marrow Liver Skin Head and neck Bone

How do we figure out which type you have? Physical Exam Cardiac, respiratory, abdominal Lymph nodes Biopsy FNA Incisional biopsy Excisional biopsy Laboratory CBC and differential LDH (prognostic marker in NHL) ESR (important in HL) Bone marrow aspirate/biopsy

Biopsies

Why is pathology important? Need to determine the most appropriate therapy Some of the criteria for diagnosis are very specific and lead to specific treatment choices For example: CD20 positive by immunohistochemistry: use of rituximab Burkitt lymphoma: specific chromosome change in lymphoma cells, specific chemotherapy treatment

Molecular analysis Morphology Immunohistochemistry Cytogenetics Gene expression profiling

Staging The # of staging investigations is dependent on the type of lymphoma and goals of therapy. Staging is used to determine: Extent of disease Bulk of tumour mass Potential for complications Type of treatment

Ann Arbor Staging System Stage I Stage II Stage III Stage IV A absence of any B symptoms B Unexplained fever, drenching sweats or weight loss Bulky > 10 cm mass on imaging

International Prognostic Index (IPI) Evaluates 5 variables: Age Stage Performance status: what is the impact of lymphoma (or other medical problems) on daily life how sick are you? Number of extranodal sites LDH https://www.qxmd.com/calculate/calculator_64/diffuse-large-b-cell-lymphoma-prognosis-r-ipi

Diffuse large B cell (DLBCL) Most common type of NHL, 30-40% of cases Cancer cell appearance led to name cells are large and spread out Can develop in lymph nodes or other areas like the intestines, skin, bone, brain. Approx. 50% of patients have organ involvement at diagnosis Average age diagnosis 57, but can affect any age group

Diffuse large B cell (DLBCL) Germinal centre B cell (GCB) DLBCLs get their name because they develop from lymphoid cells residing in the germinal centre of the lymph node. Patients with GBG-derived disease generally have better outcomes. Activated B cell (ABC) DLBCLs develop from B cells that are in the process of differentiating from germinal centre B cells to plasma cells. ABC DLBCL is associated with a poorer outcome than GCB DLBC.

Diffuse large B cell (DLBCL) Primary mediastinal B cell lymphoma (PMBL) Primary central nervous system (CNS) lymphoma EBV-positive DLBCL of the elderly T-cell/histiocyte-rich large B cell lymphoma Primary effusion lymphoma (PEL) Intravascular large B cell lymphoma (ILCL) ALK-positive large B cell lymphoma Double-expressor lymphomas (DEL)

Burkitt lymphoma Named after Dr. Denis Burkitt Affects children (usually 5-10 yrs) and accounts for 30-40% of childhood lymphomas Affects adults (usually 30-50 yrs) Can affect other organs like eyes, ovaries, kidneys, CNS or glandular tissues or jaw Treatment often involves intrathecal chemotherapy

Mantle cell lymphoma (MCL) Develops in the outer edge of a lymph node called the mantle zone Rare, 5% of NHLs, usually affecting men over age 50 Often have many lymph nodes, one or more organ (often GI tract) and bone marrow involved Often diagnosed late-stage Frequently relapses Mantle Cell Lymphoma International Prognostic Index (MIPI): low-, intermediate- and high-risk.

Hodgkin lymphoma Named after Dr. Thomas Hodgkin, who described the disease in 1832 1000 cases/year in Canada Two peaks: young adults and elderly Can be difficult to diagnose Cancer cells are in minority in affected nodes > 80% curable with chemotherapy +/- radiation HL Reed- Steinberg Normal cell is the malignant cell

Gray zone lymphoma (GZL) Rare, but generally seen in teens & young adults Often presents with a large tumour in the chest area (mediastinum) Has features of both a large B cell lymphoma and Hodgkin, and is more aggressive Can spread to other organs

T Cell lymphoma Account for 10% of NHLs Peripheral T-cell lymphoma general term referring to 10+ subtypes Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) Anaplastic large cell lymphoma (ALCL) Angioimmunoblastic Lymphoma Nasal NK/T-cell Lymphomas Lymphoblastic Lymphoma

Overview of primary treatment options Treatment Option Chemotherapy Radiation Therapy Immunotherapy Transplantation Description Use of drugs to kill lymphoma cells Use of high-energy rays to kill lymphoma cells or slow their growth Use of agents designed to target and destroy lymphoma cells Infusion of healthy stem cells/bone marrow to help the body restore its supply of healthy blood cells Balance potential toxicity against effectiveness

Chemotherapy Backbone of many cancer treatments Damages DNA, leading to cell death Systemic Affects all growing cells Cancer cells Blood cells Lining of GI tract Hair

Common chemotherapy regimens CHOP - with or without R (Rituxan) Cyclophosphamide Doxorubicin Vincristine Prednisone pills daily x 5 days By IV every 3 weeks 4 cycles if radiation is also part of the plan 6 cycles most often 8 cycles in some circumstances (young people with big masses or other problems)

Common chemotherapy regimens CVP with or without R Cyclophosphamide Vincristine Prednisone pills daily x 5 days By IV every 3 weeks For a usual total of 6 to 8 cycles unless disease progression or unacceptable toxicity occurs

Common chemotherapy regimens CHOEP, with or without R Cyclophosphamide Doxorubicin Vincristine Etoposide Prednisone pills daily x 5 days By IV every 3 weeks

Chemotherapy treatments ABVD, typical HL treatment Adriamycin Bleomycin Vinblastine Dacarbazine 1 cycle = 2 treatments and is given over 4 weeks ABVD is given every 2 weeks (A and B parts)

Immunotherapy Also called biologic therapy Drugs designed to boost the body s natural defenses against cancer Generally fewer side effects than traditional chemotherapy Sometimes used alone, but often combined with chemotherapy

Monoclonal antibodies Antibodies developed against cancer cells can be administered to patients to destroy the tumour Examples: Rituximab Obinutuzumab Brentuximab vedotin Only work for B cell lymphomas

Why add rituximab? Addition of anti- CD20 antibody rituximab to chemotherapy: improvement in survival. Collier et al, ASH 2009

Radiation Medical uses of radiation: 1. Diagnostic: low doses of radiation to take images of internal body structure i.e. chest X-ray 2. Therapeutic: higher doses of radiation to kill cancer cells Difference between the two is the amount of energy. Therapeutic radiation can use up to 1,000 times the energy of diagnostic radiation.

Radiation X-ray beams interact with atoms, creating a reaction that leads to cell DNA damage Damage prevents the cells from dividing and growing Lymphocytes are the most sensitive cells in the body to radiation, so can use lower doses of radiation compared to what is used to treat solid tumours.

Radiation Linear Accelerators Machines do not use radioactive sources but instead use electricity to produce X-rays and electrons. Versatile as they can produce different energies of radiation, to minimize the normal tissue affected.

Radiation Applies to localized disease May not be used in all types of aggressive NHL Generally treatment is given daily for 4 weeks (Monday to Friday X 4 weeks = 20 treatments or fractions ) Side effects based on the area that is being radiated (skin and tissue beneath it)

Common radiation fields

Radiation Intensity modulated beams (IMRT): Sinus location lymphoma

Radiation IMRT: Gastric lymphoma

Combination therapy Chemotherapy + radiation Radiation (radioactive isotopes) + immunotherapy = radioimmunotherapy Chemotherapy + immunotherapy = chemoimmunotherapy

Treatment outcomes Variable, depend on many things. Greatest chance of cure with initial treatment Favourable group (IPI score): 90% relapse-free Intermediate prognosis: 60-70% Unfavourable: 40-50% relapse-free Long-term remission rates lower for elderly, T cell lymphoma, certain subtypes of B cell (defined by chromosomes, for instance)

Relapse/refractory Many other treatments available, goals of therapy change Single agent chemotherapy drugs Combinations (occasionally) Radiation to local areas causing symptoms Clinical trials of new agents Clarification of goals with your oncologist is very important

Relapse/refractory For young patients: stem cell transplantation considered best option Autologous stem cells (patients own) Uses very high dose of chemotherapy to try to eliminate resistant lymphoma cells Only beneficial if lymphoma responds to a second chemotherapy regimen

Stem cell transplant (SCT) Autologous Use own cells Low treatment related mortality High rates of remission Transplant strategies vary centre-to-centre

Stem cell transplant (SCT) Allogeneic Rare HLA matched sibling or matched unrelated donor 1 in 4 chance of sibling being a match Graft versus lymphoma: good! Graft versus host disease: can be very bad, including fatal, and life long Higher treatment related mortality

Side effects of treatment Short term: Hair loss Nausea, vomiting: controllable with medication Fatigue Fever: need a thermometer! If >38.3 or 101.5 o get a blood test (even Sunday afternoon ) Low blood counts

Other possible issues Heart function: Small chance of serious damage-may need monitoring Peripheral neuropathy (numb hands, feet) Difficulty with memory, concentration (multi-tasking) chemobrain Fertility

Other possible issues Secondary cancers Work/school Going out in public, infection risks Immunization